It might also be beneficial to combine anti-angiogenic agents with multifunctional adipokines such as leptin. For example, whereas other inhibitors could block leptin-induced angiogenesis in ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

Specific blockade of DLL4, alone or in combination with other angiogenesis inhibitors, provides the exciting possibility of benefiting patients with tumours that are resistant to anti-VEGF therapies.

Adding anlotinib to standard temozolomide-based chemoradiotherapy significantly extended PFS for newly diagnosed glioblastoma ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...